Precision Site-Specific Conjugation for Enhanced Biotherapeutic Half-Life and Bioactivity. Traditional PEGylation methods often result in heterogeneous mixtures and impaired protein function due to random attachment. CD Biosynsis provides professional Cysteine-Specific PEGylation Services, utilizing the unique reactivity of the thiol group to achieve surgical precision in protein modification. By introducing or leveraging specific cysteine residues, we enable the production of monodisperse conjugates that retain maximum biological activity while significantly extending circulatory half-life and improving stability.
Get a Technical QuoteOur platform transforms therapeutic proteins and enzymes into long-acting, highly stable biopharmaceuticals through advanced sulfhydryl chemistry. We specialize in overcoming the bioactivity loss associated with conventional random modification.
| Service Tier | Technical Focus | Primary Application | Standard Deliverables |
|---|---|---|---|
| Half-Life Extension | Site-specific Maleimide chemistry | Cytokines (e.g., G-CSF, Interferon) | Purified Conjugate + PK Profile |
| Bioactivity Preservation | In silico design & surface mutation | Anticoagulants (e.g., Hirudin) | Activity Assay + Stability Data |
| Enzyme Longevity | Sulfhydryl-specific polymer coupling | Detoxification Enzymes (e.g., PTE) | Conjugate Purity & Kinetic Data |
| Oxidation-Free Conjugation | Cysteine-protected CuAAC (Click) | Fragile therapeutic proteins | High-Activity Conjugates |
1. In Silico Site Selection
2. Cysteine Mutant Engineering
3. Site-Specific Conjugation
4. Validation & Characterization
Structural analysis to identify optimal mutation sites via molecular dynamics and surface accessibility mapping.
Formal project proposal and Mutual NDA signing.
Constructing and expressing cysteine mutants in optimized chassis (E. coli, Yeast, or Mammalian systems).
Screening for mutants with preserved folding and native bioactivity.
Executing controlled PEGylation reactions, including Maleimide coupling or protected "Click" chemistry.
Isolating monoconjugated species via high-resolution Ion Exchange (IEX) and SEC chromatography.
Characterization via MALDI-TOF MS, SDS-PAGE, and bioactivity assays to verify purity and target function.
Final delivery of purified conjugates and comprehensive analytical validation reports.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in biotherapeutic engineering.
Development of PEGylated IFN-β often faces copper-mediated oxidation during CuAAC (Click) reactions. By utilizing specific cysteine residues as monothiol reducing agents, our team prevents oxidative damage to the protein backbone, ensuring high purity and stability while maintaining complex bioactivity.
(Reference: IFN Beta-1b Improvement, 2020)
Random PEGylation of G-CSF typically leads to significantly reduced activity. By introducing a specific cysteine residue and applying Maleimide-PEG chemistry, we achieve a site-specific conjugate that retains high biological activity while dramatically extending serum half-life, offering a safer alternative to conventional formulations.
(Reference: Site-Specific PEGylated G-CSF, 2020)
Phosphotriesterase (PTE) is vital for detoxifying organophosphate toxins. Through cysteine mutation and sulfhydryl-specific coupling, we effectively prevent enzyme aggregation. This modification preserves efficient hydrolytic activity while significantly prolonging in vivo circulation time for long-term bio-detoxification.
(Reference: Sulfhydryl-specific PEGylation of PTE, 2022)
Using structural modeling, we identified the Q33C mutation site in Hirudin variant 3. This site allows for PEGylation that avoids the critical binding pocket. The resulting conjugate maintains full anti-thrombin activity with a significantly extended half-life, demonstrating the power of rational cysteine engineering.
(Reference: In silico designing of hirudin variant 3, 2022)
Ready to enhance your therapeutic protein's stability and half-life?
Contact Us1. What is the benefit of Cysteine PEGylation over standard Lysine modification?
Cysteine is rare in proteins, allowing for precise control over the attachment site. Lysines are abundant, leading to random attachment and a heterogeneous mixture of products with compromised activities.
2. How do you deal with proteins that already have essential disulfide bonds?
Our in silico design process ensures that we only target or introduce "free" cysteines that are not involved in structural disulfide bridges, preventing misfolding or loss of stability.
3. Does this technique work for complex industrial enzymes?
Yes. As shown in our PTE study, cysteine-specific modification is ideal for enzymes as it prevents aggregation while keeping the active site accessible for substrate binding.
4. What PEG molecular weights are typically recommended?
We offer linear and branched PEG from 5kDa to 40kDa. 20kDa and 30kDa are common for therapeutic half-life extension to avoid renal clearance.
5. Is the Maleimide bond stable for long-term storage and clinical use?
Maleimide-thiol bonds are generally stable; however, for sensitive applications, we can offer "Next-Gen" Maleimide linkers engineered to prevent retro-Michael reactions.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.